-
Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount
Wednesday, November 2, 2016 - 12:05pm | 341Read More...Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s Voclosporin is about to begin Phase 3 trials for first-line treatment of lupus nephritis. The company could be an “ideal acquisition candidate once Phase 3 kicks off,” Mackie Research Capital’s André Uddin said in a report. Uddin...
-
UPDATE: Mackie Research Reduces PT on Eldorado Gold Corp to $15
Tuesday, May 8, 2012 - 10:12am | 115Read More...According to a research report this morning, Mackie Research reduces the PT on Eldorado Gold Corp. (NYSE: EGO) form $15.50 to $15 due to weather and slow performance on Turkey's end. Mackie Research continued, “Efemcukuru recovered 18.3koz in concentrate, which was shipped to Kisladag for final...
-
Mackie Research Downgrades Manitoba Telecom To Hold, $35 PT
Friday, May 20, 2011 - 7:15am | 27Read More...Mackie Research Capital has downgraded Manitoba Telecom Services (NYSE: MBT) from Buy to Hold and maintains its $35 price target.
-
Mackie Research Capital Comments on BCE (BCE)
Tuesday, May 10, 2011 - 9:52am | 104Read More...Mackie Research Capital provided color on BCE (NYSE: BCE) in a research report published today. BCE is expected to announce its Q1 results on Thursday, May 12. In the report, Mackie states "We are forecasting consolidated revenue to decline 0.7% Y/Y to $4.4 billion; however, we expect EBITDA to...
